Novavax (NVAX) Free Cash Flow (QoQ) (2010 - 2026)
Powered by 
Analysis
Novavax (NVAX) Free Cash Flow (QoQ) (2010 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.31 Bn | 131.46 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.65 Bn | 77.66 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.46 Bn | 58.27 Bn | 1.37 Bn |
| 4 | Moderna | 57.94 Bn | 52.80 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.05 Bn | 44.05 Bn | - |
| 6 | BeOne Medicines | 39.96 Bn | 34.86 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.16 Bn | 31.85 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.44 Bn | 27.60 Bn | - |
| 9 | Insmed | 27.32 Bn | 26.16 Bn | 358.27 Mn |
| 10 | Novavax | 1.67 Bn | 951.85 Mn | 42.45 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -117.83% |
| Mar 31, 2026 | 18.83% |
| Dec 31, 2025 | -139.01% |
| Sep 30, 2025 | 183.13% |
| Jun 30, 2025 | 31.59% |
| Mar 31, 2025 | -6.85% |
| Dec 31, 2024 | -19.78% |
| Sep 30, 2024 | -146.95% |
| Jun 30, 2024 | 444.34% |
| Mar 31, 2024 | 51.28% |
| Dec 31, 2023 | -221.07% |
| Sep 30, 2023 | 67.69% |
| Jun 30, 2023 | 48.20% |
| Mar 31, 2023 | -145.24% |
| Dec 31, 2022 | -122.36% |
| Sep 30, 2022 | 67.60% |
| Jun 30, 2022 | -85.58% |
| Mar 31, 2022 | 70.39% |
| Dec 31, 2021 | -130.53% |
| Sep 30, 2021 | -219.40% |